BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, Leise MD. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol. 2017;15:767-775.e3. [PMID: 28013117 DOI: 10.1016/j.cgh.2016.11.034] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Shaikh A, Goli K, Rich NE, Benhammou JN, Khaderi S, Hernaez R, Agopian VG, Vierling JM, Kim D, Ahmed A, Goss JA, Rana A, Kanwal F, Cholankeril G. Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplantation Direct 2022;8:e1313. [DOI: 10.1097/txd.0000000000001313] [Reference Citation Analysis]
2 Hernaez R, Kanwal F, El-Serag HB. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology 2018;68:7-9. [PMID: 29315712 DOI: 10.1002/hep.29776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li P, Fan H, He Q. Pretransplant diabetes mellitus predicts worse outcomes of liver transplantation: evidence from meta-analysis. J Endocrinol Invest 2018;41:211-21. [DOI: 10.1007/s40618-017-0721-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu J, Mau Lo C, Man K. Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering 2021. [DOI: 10.1016/j.eng.2021.11.012] [Reference Citation Analysis]
5 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patel YA, Yao J, Proeschold-Bell RJ, Niedzwiecki D, Goacher E, Muir AJ. Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. Dig Dis Sci 2021;66:2956-63. [PMID: 32968965 DOI: 10.1007/s10620-020-06616-5] [Reference Citation Analysis]
7 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: De novo neoplasms after liver transplantation. Curr Opin Organ Transplant. 2018;23:187-195. [PMID: 29324517 DOI: 10.1097/mot.0000000000000499] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
9 Aby ES, Lake JR. Basic principles of liver allocation and development over the years. Curr Opin Organ Transplant 2020;25:99-103. [PMID: 32073495 DOI: 10.1097/MOT.0000000000000732] [Reference Citation Analysis]
10 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 167] [Article Influence: 45.3] [Reference Citation Analysis]
11 Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomark Med 2020;14:855-67. [PMID: 32808827 DOI: 10.2217/bmm-2019-0564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Shingina A, DeWitt PE, Dodge JL, Biggins SW, Gralla J, Sprague D, Bambha K. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC. Transplantation. 2019;103:140-148. [PMID: 30451739 DOI: 10.1097/tp.0000000000002497] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
13 Yang JD, Leise MD. Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus. Liver Int 2017;37:809-11. [PMID: 28544691 DOI: 10.1111/liv.13422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
15 Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71:907-916. [PMID: 31309602 DOI: 10.1002/hep.30858] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
16 Croome KP, Mathur AK, Pungpapong S, Lee DD, Moss AA, Rosen CB, Heimbach JK, Taner CB. Equivalent Outcomes With Retransplantation and Primary Liver Transplantation in the Direct-acting Antiviral Era. Transplantation 2019;103:1168-74. [DOI: 10.1097/tp.0000000000002460] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Chandrakumaran A, Siddiqui MS. Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. Gastroenterol Clin North Am 2020;49:165-78. [PMID: 32033762 DOI: 10.1016/j.gtc.2019.09.005] [Reference Citation Analysis]
18 Aggarwal A, Te HS, Verna EC, Desai AP. A National Survey of Hepatocellular Carcinoma Surveillance Practices Following Liver Transplantation. Transplant Direct 2021;7:e638. [PMID: 33324743 DOI: 10.1097/TXD.0000000000001086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Savier E, Brustia R, Golmard JL, Scatton O; Collaborators. Influence of 4 preservation solutions on ICU stay, graft and patient survival following liver transplantation. J Visc Surg 2020;157:87-97. [PMID: 31548152 DOI: 10.1016/j.jviscsurg.2019.09.001] [Reference Citation Analysis]
20 Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM, Chu J, El-Serag HB. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018;155:1828-1837.e2. [PMID: 30144434 DOI: 10.1053/j.gastro.2018.08.024] [Cited by in Crossref: 176] [Cited by in F6Publishing: 178] [Article Influence: 44.0] [Reference Citation Analysis]
21 Asrani SK, Jennings LW, Kim W, Kamath PS, Levitsky J, Nadim MK, Testa G, Leise MD, Trotter JF, Klintmalm G. MELD‐GRAIL‐Na: Glomerular Filtration Rate and Mortality on Liver‐Transplant Waiting List. Hepatology 2020;71:1766-74. [DOI: 10.1002/hep.30932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
22 Liu X, Jiang N, Xu X, Liu C, Liu Z, Zhang Y, Kang W. Anti-Hepatoma Compound Determination by the Method of Spectrum Effect Relationship, Component Knock-Out, and UPLC-MS2 in Scheflera heptaphylla (L.)Frodin Harms and Its Mechanism. Front Pharmacol 2020;11:1342. [PMID: 33013373 DOI: 10.3389/fphar.2020.01342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state: Liver Cancer in the United States. CA: A Cancer Journal for Clinicians 2017;67:273-89. [DOI: 10.3322/caac.21402] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 16.2] [Reference Citation Analysis]
24 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Bezinover D, Geyer NR, Dahmus J, Chinchilli VM, Stine JG. A decline in functional status while awaiting liver transplantation is predictive of increased post-transplantation mortality. HPB (Oxford) 2021:S1365-182X(21)01664-6. [PMID: 34772623 DOI: 10.1016/j.hpb.2021.10.008] [Reference Citation Analysis]
27 Han S, Yang JD, Sinn DH, Kim JM, Choi GS, Jung G, Ahn JH, Kim S, Ko JS, Gwak MS, Kwon CHD, Leise MD, Gwak G, Heimbach JK, Kim GS. Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. Annals of Surgery 2018;268:1043-50. [DOI: 10.1097/sla.0000000000002318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tammineedi D, Eisert J, Ukken J, Froehlich M, Azab M, Liu X, Yoo JW. More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations. Journal of Hepatology 2018;68:218-9. [DOI: 10.1016/j.jhep.2017.08.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Cullaro G, Rubin JB, Mehta N, Lai JC. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl 2020;26:349-58. [PMID: 31610089 DOI: 10.1002/lt.25662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
30 Metselaar HJ, van den Berg AP, Coenraad MJ. Why we need fairer allocation rules for patients with hepatocellular carcinoma awaiting a liver transplant? Transpl Int 2017;30:1092-4. [PMID: 28493615 DOI: 10.1111/tri.12980] [Reference Citation Analysis]
31 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
32 Boteon Y, Flores Carvalho MA, Panconesi R, Muiesan P, Schlegel A. Preventing Tumour Recurrence after Liver Transplantation: The Role of Machine Perfusion. Int J Mol Sci 2020;21:E5791. [PMID: 32806712 DOI: 10.3390/ijms21165791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
33 Shalaby S, Taborelli M, Zanetto A, Ferrarese A, D'Arcangelo F, Gambato M, Senzolo M, Russo FP, Germani G, Boccagni P, Ettorre GM, Baccarani U, Lauro A, Galatioto L, Rendina M, Petrara R, De Rossi A, Nudo F, Toti L, Fantola G, Vennarecci G, Risaliti A, Pinna AD, Gruttadauria S, Di Leo A, Rossi M, Tisone G, Zamboni F, Cillo U, Piselli P, Serraino D, Burra P; Italian Transplant and Cancer Cohort Study. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study. Transpl Int 2021;34:743-53. [PMID: 33492715 DOI: 10.1111/tri.13831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Pan L, Feng F, Wu J, Li L, Xu H, Yang L, Xu K, Wang C. Diosmetin inhibits cell growth and proliferation by regulating the cell cycle and lipid metabolism pathway in hepatocellular carcinoma. Food Funct 2021. [PMID: 34755740 DOI: 10.1039/d1fo02111g] [Reference Citation Analysis]
35 Cheng JT, Volk ML. Positron Emission Tomography Scan in Detecting and Locating Extrahepatic Recurrent Hepatocellular Carcinoma Post Orthotic Liver Transplant. Prog Transplant 2020;30:396-7. [PMID: 32912112 DOI: 10.1177/1526924820958135] [Reference Citation Analysis]
36 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
37 Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol 2019; 11(3): 261-272 [PMID: 30967904 DOI: 10.4254/wjh.v11.i3.261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
38 Yang JD, Leise MD. Reply. Clin Gastroenterol Hepatol 2017;15:1814. [PMID: 28782669 DOI: 10.1016/j.cgh.2017.07.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Yohanathan L, Heimbach JK. The Impact of Allocation Changes on Patients with Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:657-63. [DOI: 10.1016/j.cld.2020.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343 [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
41 Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-Based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation 2020. [PMID: 33323764 DOI: 10.1097/TP.0000000000003575] [Reference Citation Analysis]
42 Cunha GM, Tamayo-murillo DE, Fowler KJ. LI-RADS and transplantation: challenges and controversies. Abdom Radiol 2021;46:29-42. [DOI: 10.1007/s00261-019-02311-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
44 Young K, Liu B, Bhuket T, Wong RJ. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals. J Clin Exp Hepatol. 2020;10:581-589. [PMID: 33311895 DOI: 10.1016/j.jceh.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
47 Moctezuma-Velazquez C, Márquez-Guillén E, Torre A. Obesity in the Liver Transplant Setting. Nutrients 2019;11:E2552. [PMID: 31652761 DOI: 10.3390/nu11112552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
48 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
50 Bhat M, Clotet-Freixas S, Baciu C, Pasini E, Hammad A, Ivanics T, Reid S, Azhie A, Angeli M, Ghanekar A, Fischer S, Sapisochin G, Konvalinka A. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. Clin Proteomics 2021;18:27. [PMID: 34794390 DOI: 10.1186/s12014-021-09333-x] [Reference Citation Analysis]
51 Ivanics T, Shwaartz C, Claasen MPAW, Patel MS, Yoon P, Raschzok N, Wallace D, Muaddi H, Murillo Perez CF, Hansen BE, Selzner N, Sapisochin G. Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. Transpl Int 2021;34:1444-54. [PMID: 33977568 DOI: 10.1111/tri.13903] [Reference Citation Analysis]
52 Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl. 2017;23:1103-1112. [PMID: 28544587 DOI: 10.1002/lt.24790] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
53 Heimbach JK. Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma. Semin Liver Dis 2020;40:358-64. [PMID: 32942324 DOI: 10.1055/s-0040-1709492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Liu X, Lee JL, Yoo JW. More Benefits From Interrupted Time Series in Evaluating the Recent Market Release of Direct-Acting Antiviral Agents and State Medicaid Reimbursement Programs. Clinical Gastroenterology and Hepatology 2017;15:1813. [DOI: 10.1016/j.cgh.2017.05.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402:863-871. [PMID: 28755240 DOI: 10.1007/s00423-017-1609-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
56 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Pamecha V, Sinha PK, Rajendran V, Patil NS, Mohapatra N, Rastogi A, Patidar Y, Choudhury A. Living donor liver transplantation for hepatocellular carcinoma in Indian patients- Is the scenario different? Indian J Gastroenterol 2021;40:295-302. [PMID: 34019241 DOI: 10.1007/s12664-020-01138-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
59 Iavarone M, Invernizzi F. Liver transplant for hepatocellular carcinoma: A heavyweight therapeutic option in need of a new policy on liver graft allocation. Dig Liver Dis 2018;50:1351-2. [PMID: 30316790 DOI: 10.1016/j.dld.2018.09.018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Wallace MC, Knuiman M, Huang Y, Garas G, Adams LA, MacQuillan G, Preen DB, Jeffrey GP. The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable. Dig Dis Sci 2018;63:2277-84. [PMID: 29808245 DOI: 10.1007/s10620-018-5132-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Mazur RD, Goldberg DS. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers. Liver Transpl 2019;25:1800-10. [PMID: 31539195 DOI: 10.1002/lt.25644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Adeniji N, Arjunan V, Prabhakar V, Tulu Z, Kambham N, Ahmed A, Kwo P, Dhanasekaran R. Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome. Clin Transplant 2020;34:e14128. [PMID: 33098134 DOI: 10.1111/ctr.14128] [Reference Citation Analysis]
63 Izzy M, Addissie BD, Arab JP, Hilscher MB, Cartee A, Lee DC, Lee Y, Fletcher JG, Keaveny TM, Sanchez W. Triple-Phase Computed Tomography May Replace Dual-Energy X-ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates. Liver Transpl 2021;27:341-8. [PMID: 33098253 DOI: 10.1002/lt.25926] [Reference Citation Analysis]
64 Crespo G, Trota N, Londoño M, Mauro E, Baliellas C, Castells L, Castellote J, Tort J, Forns X, Navasa M. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. Journal of Hepatology 2018;69:11-7. [DOI: 10.1016/j.jhep.2018.02.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
65 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018; 24(32): 3626-3636 [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
66 Claasen MPAW, Ivanics T, Gravely A, Sapisochin G. Prognostic risk scores for liver transplantation: game changers or statistical artworks? Hepatobiliary Surg Nutr 2021;10:553-7. [PMID: 34430542 DOI: 10.21037/hbsn-21-258] [Reference Citation Analysis]
67 Romano DN, Mokuolu DC, Katz DJ, DeMaria S Jr. Orthotopic liver transplant in the pregnant recipient: A systematic review of preoperative management and maternal and fetal outcomes. Clin Transplant 2021;35:e14269. [PMID: 33615548 DOI: 10.1111/ctr.14269] [Reference Citation Analysis]
68 Young K, Liu B, Bhuket T, Gish RG, Wong RJ. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. J Viral Hepat. 2019;26:350-361. [PMID: 30412318 DOI: 10.1111/jvh.13039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
69 Nagai S, Safwan M, Kitajima T, Yeddula S, Abouljoud M, Moonka D. Disease-specific waitlist outcomes in liver transplantation - a retrospective study. Transpl Int 2021;34:499-513. [PMID: 33423330 DOI: 10.1111/tri.13814] [Reference Citation Analysis]
70 Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239 [PMID: 31143073 DOI: 10.3748/wjg.v25.i18.2229] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]